Phase 3 CheckMate 067 trial of nivolumab and ipilimumab combination or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma | Dr James Larkin...

Phase 3 CheckMate 067 trial of nivolumab and ipilimumab combination or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma | Dr James Larkin...

User Photo
EMJ

5 years
1,160 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden, London, UK, discusses the phase 3 CheckMate 067 trial. The results of this trial demonstrate a superior progression-free survival of nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) regimen or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma.



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
>